Non Small Cell Lung Cancer
Conditions
Brief summary
Nivolumab is an approved treatment option for patients with previously treated advanced NSCLC, based on the survival benefit shown versus docetaxel in randomized phase III trials in second line. However, the profile of treatment and even patient outcomes are often different in routine clinical practice than in a clinical trial setting. Furthermore, the financial impact of an approved therapy is often largely unknown. This study will record the efficacy and tolerability of Nivolumab in previously treated patients with NSCLC and describe the treatment patterns and economic impact in real-world settings in Greece.
Detailed description
Patients with advanced NSCLC who had received nivolumab as 2nd line and beyond, between October 2015 and November 2019, in HeCOG clinical centres in Greece, were enrolled. Information regarding detailed patient and treatment characteristics including post-nivolumab therapies, efficacy, and safety data of nivolumab treatment and additionally data on costs and other economic values are collected, analysed and compared with historical data in order to describe the real-world patterns of Nivolumab use in 2nd line NSCLC therapy in Greece.
Interventions
None listed
Sponsors
Hellenic Cooperative Oncology Group
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of advanced Squamous or Non-Squamous NSCLC (histologically or cytologically confirmed), who had relapsed after 1 prior platinum-based systemic treatment and who received treatment with nivolumab * nivolumab treatment received in participating HeCOG centres between October 2015 and November 2019 * Alive patients must have signed and dated the study approved written informed consent form in accordance with regulatory and institutional guidelines, obtained before any protocol-related procedures that are not part of normal patient care.
Exclusion criteria
* Alive patients who do not want to sign and date the study approved written informed consent form * Patients that participated in any other clinical trial prior or after nivolumab treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description of real world clinical use of Nivolumab in pre-treated NSCLC patients | approximately 12 months | Real-world clinical use |
| overall survival (OS) | approximately 12 months | Measured from time of initial treatment with nivolumab until date of death |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate (ORR) as assessed by investigator | approximately 12 months | the number of participants with best overall response (OR) of confirmed complete response (CR) or partial response (PR) divided by the total number of participants who received treatment |
| Cost-effectiveness | approximately 12 months | economic evaluations based on costs of Nivolumab clinical use in Greece |
Outcome results
None listed